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Abstract 
Mucopolysaccharidosis (MPS) is a metabolic storage disorder caused by the deficiency of any lysosomal 
enzyme required for the breakdown of glycosaminoglycans. A 15-month-old Boston Terrier presented with 
clinical signs consistent with lysosomal storage disease including corneal opacities, multifocal central 
nervous system disease and progressively worsening clinical course. Diagnosis was confirmed at 
necropsy based on histopathologic evaluation of multiple organs demonstrating accumulation of 
mucopolysaccharides. Whole genome sequencing was used to uncover a frame-shift insertion affecting 
the alpha-L-iduronidase (IDUA) gene (c.19_20insCGGCCCCC), a mutation confirmed in another Boston 
Terrier presented 2 years later with a similar clinical picture. Both dogs were homozygous for the IDUA 
mutation and shared coat colors not recognized as normal for the breed by the American Kennel Club. In 
contrast, the mutation was not detected in 120 unrelated Boston Terriers as well as 202 dogs from other 
breeds. Recent inbreeding to select for recessive and unusual coat colors may have concentrated this 
relatively rare allele in the breed. The identification of the variant enables ante-mortem diagnosis of 
similar cases and selective breeding to avoid the spread of this disease in the breed. Boston Terriers 
carrying this variant represent a promising model for MPS I with neurological abnormalities in humans. 
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Whole genome sequencing for 
mutation discovery in a single case 
of lysosomal storage disease (MpS 
type 1) in the dog
tamer A. Mansour1,2*, Kevin D. Woolard3, Karen L. Vernau4, Devin M. Ancona5, 
Sara M. thomasy4,6, Lionel Sebbag7, Bret A. Moore4, Marguerite F. Knipe8, 
Haitham A. Seada9, Tina M. cowan10, Miriam Aguilar1, C. titus Brown1 & Danika L. Bannasch1*
Mucopolysaccharidosis (MPS) is a metabolic storage disorder caused by the deficiency of any lysosomal 
enzyme required for the breakdown of glycosaminoglycans. A 15-month-old Boston Terrier presented 
with clinical signs consistent with lysosomal storage disease including corneal opacities, multifocal 
central nervous system disease and progressively worsening clinical course. Diagnosis was confirmed 
at necropsy based on histopathologic evaluation of multiple organs demonstrating accumulation of 
mucopolysaccharides. Whole genome sequencing was used to uncover a frame-shift insertion affecting 
the alpha-L-iduronidase (IDUA) gene (c.19_20insCGGCCCCC), a mutation confirmed in another Boston 
Terrier presented 2 years later with a similar clinical picture. Both dogs were homozygous for the IDUA 
mutation and shared coat colors not recognized as normal for the breed by the American Kennel Club. 
In contrast, the mutation was not detected in 120 unrelated Boston Terriers as well as 202 dogs from 
other breeds. Recent inbreeding to select for recessive and unusual coat colors may have concentrated 
this relatively rare allele in the breed. The identification of the variant enables ante-mortem diagnosis 
of similar cases and selective breeding to avoid the spread of this disease in the breed. Boston Terriers 
carrying this variant represent a promising model for MpS i with neurological abnormalities in humans.
Mucopolysaccharidosis (MPS) is a type of lysosomal storage disease caused by a deficiency of enzymes integral 
to the breakdown of glycosaminoglycans (GAGs). This serious condition, described in many species including 
humans and dogs, leads to the accumulation of metabolites of the GAG degradation pathway within lysosomes 
along with increased urinary excretion of these metabolites1. There are 11 known enzymes that regulate the catab-
olism of four different GAGs. The GAGs affected in each variant of MPS are dependent upon which enzyme is 
deficient2.
In people, MPS is a chronic disease with a progressive course. Neurological abnormalities are a major com-
ponent of the disease. The progressive cerebral disease typically occurs in MPS III and severe forms of MPS I, 
II, and VII but chronic hearing loss and vision impairment can occur in all types. Thickening of meninges and 
diffuse changes to the brain's white matter are also common3,4. Most MPS types, except for MPS III, are associated 
with skeletal abnormalities, joint disease, short stature and abnormal facies5. Cardiovascular dysfunctions like 
valvular heart disease, narrowing of coronary arteries, and eccentric hypertrophy are universal to all subtypes 
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but more common in MPS I, II, and VI6. Corneal opacification is a common ocular abnormality in MPS I, VI, 
VII, less common in MPS IV, and discrete if any in MPS II7,8. Other somatic manifestations may include recur-
rent infections, obstructive airway, enlarged tongue, and hepatosplenomegaly1,9. The clinical characterization 
of disease subtypes may be challenging because of overlap in clinical features and the clinical heterogeneity in 
each subtype1,10–13. Even with the same enzyme affected, different underlying causative mutations have different 
clinical presentations14,15.
Animal models have become extremely important in the continued investigation of MPS disorders16,17. Unlike 
rodent models in which specific genetic mutations are induced, dogs with naturally occurring disease represent 
an accurate model that better reflect the complex genetic, environmental, and physiological variation present in 
humans18. Several canine models of MPS were characterized. Specifically, MPS types I, II, IIIA, IIIB, VI, and VII 
have been identified in dogs19. Impaired enzymes and accumulated GAGs in different dog breeds perfectly match 
their corresponding subtypes in human (Supplementary Table S1). Moreover, MPS in dogs recapitulates most 
of the clinical features in human patients17, however some discrepancies have been documented20,21. The only 
canine model of MPS I is described in the Plott Hound breed, with dogs presenting with severe joint and bone 
disease but no detectable neurologic deficits22. Given the heterogeneity of disease subtypes in humans, and the 
incomplete representation of the whole spectrum of MPS I manifestations in dogs, each new spontaneous muta-
tion in dogs comes with a new golden opportunity to better characterize the disease and utilize canine models for 
translational research.
MPS is autosomal recessive in dogs, except for MPS II which has an X-linked mode of inheritance16. Causative 
genetic variants were found in coding sequences of several lysosomal enzymes for MPS IIIA23,24, MPS VI25,26, and 
MPS VII in dog patients27–29. However, MPS I in Plott Hounds was explained by the retention of intron 1 in the 
alpha-L-iduronidase (IDUA) gene caused by a mutation in the donor splice site. Some of the MPS mutations are 
shared across multiple breeds while others appear to be breed specific30,31.
In this work, a Boston Terrier dog was presented to the UC Davis William R Pritchard Veterinary Medical 
Teaching Hospital (VMTH) with progressive neurological and ophthalmic abnormalities. Urine metabolic 
screening, bilateral corneal deposits, and multi-organ infiltration of mucopolysaccharides confirmed on nec-
ropsy were all highly suggestive of MPS disease. A pipeline for the identification of the causative mutation in a 
single MPS patient is presented here using whole genome sequencing (WGS). A frame shift mutation in IDUA 
gene caused by an 8-nucleotide insertion was identified as the causative mutation. The mutation was confirmed 
in a second Boston Terrier dog examined at the VMTH 2 years later. The clinical presentation and pathological 
analysis of this newly identified sequence variant is described.
Results
A 15-month-old female spayed Boston Terrier was presented to the VMTH with a 2-month history of pro-
gressive generalized ataxia and abnormal mentation. The dog had been ataxic and lethargic since 4–6 months 
of age. On physical examination, bilateral grade I/IV medial patellar luxations and bilateral carpal and tarsal 
hyperextension were noted. Skull conformation was atypical for the patient's age and breed, characterized by a 
broad and dome-shaped head, wide set eyes and shallow orbits. The coat color was chocolate brown (Fig. 1A), 
an atypical feature that is not standard according to the Boston Terrier guidelines from the American Kennel 
Club. Ophthalmic examination revealed mild conjunctival hyperemia, superficial corneal neovascularization, 
and an approximately 7 ml ill-defined geographical area of crystalline white deposits present in the anterior to 
mid-corneal stroma axially. Ocular changes were bilateral and symmetrical. Tear production and intraocular 
pressures were adequate in both eyes. Neuro-ophthalmic examination was unremarkable, with an intact menace 
response, dazzle, palpebral and pupillary light reflexes. Neurological examination showed mild obtundation, gen-
eralized ataxia, and delayed to absent proprioceptive positioning in all limbs. All segmental reflexes and cranial 
nerve reflexes/responses were appropriate. The patient was reactive upon palpation of the entire vertebral column; 
however, overt apparent pain was not elicited. These neurological abnormalities were consistent with multifocal 
central nervous system disease.
Results of the complete blood count, biochemical profile, and urinalysis were unremarkable. Thoracic radi-
ographs showed multifocal intervertebral disc space narrowing with spondylosis deformans and moderate 
hepatomegaly. On abdominal ultrasound the liver was mildly enlarged and diffusely hyperechoic. On magnetic 
resonance imaging (MRI) of the brain there was generalized ventriculomegaly (Fig. 1E). An MRI of the cervical 
spinal cord showed spinal stenosis secondary to a protruding intervertebral disc into the spinal canal (arrow-
heads) (Fig. 1J). A lysosomal storage disease was the top differential diagnosis for the patient given the dog's 
young age, slow deterioration of clinical signs, multifocal central nervous system disease, corneal deposits, skull 
and vertebral column abnormalities, hepatomegaly, and unremarkable blood work. Subsequent urine metabolic 
screening was positive, suggestive of MPS.
Based on worsening clinical signs and poor prognosis, the dog's owners elected for humane euthanasia fol-
lowed by necropsy. On gross assessment, the corneas were opaque white with prominent small blood vessels. The 
tongue was globally enlarged with an ulcerated nodule protruding from the left aspect of the tongue base. The 
liver was slightly enlarged. Within the heart, the septal leaflet of the tricuspid valve was diffusely thickened. The 
mitral valve was thickened by approximately 15, small, smooth-surfaced nodules present in both valvular leaflets. 
The aortic valve exhibited similar, nodular thickening. In the brain, the leptomeninges were opaque, obscuring 
vascular profiles. On cross section of the fixed brain, mild ventriculomegaly was noted within the lateral ventri-
cles. Histopathologic examination of the cornea, endocardium, gingiva, and meninges revealed variably cellular 
tissue infiltrates composed of macrophages containing abundant, vacuolated cytoplasm. On histochemical stains, 
cytoplasmic vacuoles within macrophages were positive for periodic acid Schiff (PAS) and Alcian blue stains 
consistent with glycosaminoglycan accumulation. Within the liver, the hepatic sinusoids were hypercellular, with 
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an increased number of Kupffer cells exhibiting similar cytoplasmic vacuolation and histochemical stain profiles. 
The splenic white pulp was expanded by nodular aggregates of identically appearing macrophages (Fig. 2).
WGS was performed for unbiased screening of the dog genome using the canFam3 assembly to uncover 
the underlying genetic change32. Approximately 350 million 150 bp paired-end (PE) reads were generated using 
Illumina sequencing. Approximately 323 million PE reads survived quality filtering, and a 97.14% mapping rate 
was achieved, yielding 40x coverage of the reference genome. The variant calling pipeline identified 6,168,093 
variants in total. To find the causative variant, several steps of filtration were applied based on the incidence of 
the disease, expected mode of inheritance, and functional annotation of the genomic variants. To exclude com-
mon variants in dogs, a control database of common genomic variants found in 100 dogs including 2 Boston 
Terriers with minor allele frequency >1% was used33,34. Only 150,668 variants were found to be unique to the 
affected dog. As a recessive disease, the causative mutation was expected to be a homozygous or compound 
heterozygous deleterious coding variant. Functional annotation was done to retain variants with high impact 
on their proteins’ function according to the NCBI (last modified on 9/5/17) and Ensembl (v98) annotations 
(Supplementary Table S2). Using NCBI annotations, there were 45 deleterious homozygous mutations affecting 
43 transcripts belonging to 36 genes. Also, there were 102 deleterious heterozygous mutations in the genome. 
However, compound heterozygous inheritance requires at least 2 detrimental mutations affecting both haplotypes 
of a gene. Only 25 heterozygous mutations affecting 12 genes could fulfil these conditions. According to the NCBI 
annotations, genes with known genome assembly errors were excluded from the analysis. This filter removed 17 
Figure 1. Atypical coat colors, corneal opacities and multifocal central nervous system disease. Two spayed 
female Boston Terriers age 15 months (A) and 21 months (B), with atypical chocolate coat color diagnosed with 
MPS type I. Corneal opacities characterized by white, crystalline stromal infiltrates with direct illumination 
(C) or dark, shadowing regions with retroillumination (D) in dog B. Transverse T2 weighted MR images of 
the brain at the level of the thalamus showed moderate generalized ventriculomegaly, cerebral cortical atrophy 
and a thin corpus callosum, with hyperintensity of the cerebral white matter and thalamus in dog A (E) and 
dog B (F). Lateral radiograph of cervical vertebral column in dog B showed short vertebral bodies, multifocal 
intervertebral disc space narrowing, ill-defined vertebral end plates and sondylosis deformans (G). Sagittal T2 
weighted MR images of the cervical (H,J) and thoracolumbar spinal cord (I) showed multifocal protruding 
intervertebral discs into the spinal canal (arrowheads) with spinal cord stenosis (inset transverse T2 MRI in H) 
in dog A (J) and dog B (H,).
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homozygous and 6 heterozygous variants affecting 11 and 3 genes respectively. Among the remaining 28 homozy-
gous variants, only 10 variants affecting 8 genes were annotated to have highly deleterious impact on their protein 
products based on the Ensembl annotation as well. Also, the remaining 19 heterozygous mutations had only 12 
deleterious variants affecting 6 genes according to the Ensembl annotation (Supplementary Table S2).
Further identification of the exact causative gene required a candidate gene approach. There are 11 known 
MPS causative genes in humans. We examined all possible canine gene annotations (Broad protein tracks, 
Ensembl and NCBI) to identify the corresponding canine orthologs (Supplementary Table S3). The list of can-
didate genes was examined for any detrimental homozygous or heterozygous mutations. Only the IDUA gene 
showed precisely one deleterious homozygous frame-shift insertion (c.19_20insCGGCCCCC). Due to the repet-
itive nature of the locus sequence, the insertion could have happened after any base pair from 3–19, but the 
effect on the protein sequence remains the same (Supplementary Notes). The insertion in the IDUA gene leads 
Figure 2. Systematic necropsy examination confirms type I MPS. Each row shows four sections of the 
examined tissues. The first section is stained by H&E and examined at 40x magnifications. The latter 3 sections 
are stained by H&E, PAS, and Alcian blue respectively and examined at 400x magnification. Tissue sections 
show cellular infiltration (H&E 40×). Higher magnification shows that macrophages exhibit abundant, 
vacuolated cytoplasm (H&E 400×). Macrophages are variably positive on PAS and Alcian blue stains. Bar = 100 
micrometers.
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to a premature stop, which causes a truncated protein (108 instead of 655 amino acids). The sequence causes a 
frame-shift after position number 6 and Blastp alignment35 fails to find a significant overlap between the two 
protein products. According to several protein domain databases summarized by Ensembl v9136, the mutation 
abolishes the glycosidase hydrolase domain (Supplementary Notes).
The IDUA gene insertion was confirmed by Sanger sequencing (Fig. 3A)37. To quantify the IDUA expression, 
RT-PCR was performed using RNA extracted from the patient's spleen and a matching sample from another 
unaffected Boston Terrier. The analysis shows no expression in the patient's sample (Fig. 3B and Supplementary 
Notes).
To calculate the population allele frequency, Sanger sequencing was used to genotype 120 Boston Terriers as 
well as 202 dogs from different breeds (Supplementary Table S4). The insertion (chr3  :g.91534556_91534557ins-
GGGGGCCG) was not identified in any samples in either 1 or 2 copies.
Two years after the presentation of the first case, a second female spayed Boston Terrier, with similar clini-
cal signs (abnormal mentation and trouble walking in all four limbs) was presented to the VMTH. She was 21 
months old at the time of presentation. On physical examination, she was noted to have a dilute chocolate colored 
coat, wide set eyes, a markedly domed head, and peg like incisors (Fig. 1B). A grade II/VI basilar systolic heart 
murmur was audible. The dog had bilateral central white, crystalline corneal deposits in the anterior stroma 
with superficial vascularization (Fig. 1C,D). Neurological examination showed multifocal CNS disease with mild 
obtundation, moderate ataxia and tetraparesis. Proprioceptive positioning was absent in all four legs and pain on 
cervical flexion was apparent.
On cardiac ultrasound, there was moderate aortic valve insufficiency, heterogeneous left ventricular myo-
cardium, and trace mitral valve insufficiency. A serum troponin was normal. On vertebral column radiographs, 
there was an irregular appearance of the vertebral bodies and end plates of C3–4, C4–5 and T4–8, with collapse 
of the intervertebral disc spaces and thoracic spondylosis deformans. MRI of the brain showed moderate gener-
alized ventriculomegaly and multifocal cerebral white matter, thalamic, brainstem and spinal cord T2 weighted 
and FLAIR hyperintensities (Fig. 1F–I), as well as multifocal protruding intervertebral discs into the cervical and 
thoracolumbar spinal canal with spinal cord stenosis (Fig. 1H,I). The protein of the cerebrospinal fluid sample 
was mildly elevated (42 mg/dL - normal 0–25 mg/dL), with a slightly elevated total nucleated cell count of 3 cells/
uL (normal 0–2 cells/uL). On cytological evaluation, many mononuclear cells contained abundant, large chunky 
metachromatic granules suggestive of Alder-Reilly bodies. Quantitative analysis of GAGs in urine showed a high 
level compared to unaffected controls (31.8 mg/mmol creatinine VS 2.9 mg/mmol creatinine). Sanger sequencing 
showed this case homozygous for the same insertion mutation identified in the first Boston Terrier. Since the two 
affected dogs had similar and unusual coat colors for the breed, the coat color genes of both dogs were genotyped. 
The first affected dog was found to be TYRP1b/b and MLPHD/d consistent with its chocolate coat color and the 
second dog was TYRP1b/b and MLPHd/d consistent with its dilute chocolate coat color
Discussion
MPS is a debilitating disease affecting humans, dogs and many other species17. In this work, we document the 
clinical presentation of two Boston Terriers with MPS type 1. Whole genome sequencing was used for the discov-
ery of the underlying causative mutation in one of the dogs and the same mutation was confirmed in the second 
dog.
The first Boston Terrier case was presented with multifocal central nervous system disease, corneal opacities 
and vertebral anomalies, all suggestive of a lysosomal storage disease. Urinary spot test was positive for MPS, 
and post-mortem histology of diverse tissues showed large foamy macrophages filled with clear intracytoplasmic 
vacuoles. Boston Terriers with central nervous system abnormalities described in the present report mimic the 
clinical manifestations of humans affected by severe forms of MPS I, in which progressive cerebral disease devel-
ops with depositions of the GAGs in the meninges and white matter of the brain3,4. In contrast, the only other 
model of MPS type I documented in dogs (Plott Hounds) has an earlier onset of disease causing stunted growth 
of affected animals30. MPS I in Plott Hounds is characterized by severe joint and bone disease with overt pain but 
no detectable neurologic deficiencies30. Lesions in the heart, eyes, and tongue are common to both animal models 
Figure 3. Molecular changes of the IDUA gene. (A) Sanger sequencing traces of the candidate insertion 
(c.19_20insCGGCCCCC) in the IDUA gene. (B) Semi-qRT-PCR of IDUA and RPS5 expression in spleen 
samples from affected and unaffected Boston Terriers.
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however the abnormal facies and hepatomegaly seen in Boston Terrier are typical features of the human disease 
but are not apparent in the Plott Hound dogs.
There are no published variants causing MPS in Boston Terriers despite reports about the disease in the 
breed16. Clinical diagnosis of the first Boston Terrier with MPS at the VMTH motivated the molecular diagnosis 
of the affected patient to enable the estimation of the mutant allele frequency in the Boston Terrier population. In 
the absence of suitable family structure or enough cases and controls, techniques like genetic linkage and genome 
wide association are not useful for disease gene discovery38,39. In conditions with a defined list of candidate genes, 
targeted sequencing is sometimes used40,41. However, challenges of custom enrichment, poor uniformity of cov-
erage. and unexpected candidate genes are known disadvantages of this approach42. Improved canine exome 
designs are available and cost efficient however limited by the accuracy of available annotation and restricted for 
detection of protein coding variants43. WGS not only provides extended coverage but also yields better data with 
more uniform and reliable coverage, less GC and reference biases, and even more power for detecting exome 
variants44. In dogs, WGS has been successfully used in disease gene discovery in a family trio. In the absence of 
candidate disease genes, additional genotyping of extra cases was needed45. WGS was also able to identify the 
causative coding variant of oculocutaneous albinism in candidate genes46.
In this study, WGS was used to identify all genetic variants in a single MPS case. The subsequent bioinformat-
ics pipeline filtered these variants based on the expected mode of inheritance, against a database of canine vari-
ants, and according to their expected detrimental effect on the coding sequence. This pipeline was able to reduce 
the initial 6,168,093 variants to only 10 homozygous mutations and 12 heterozygous mutations (Supplementary 
Table S2). The known pathophysiology of the disease and the previously identified mutations found in the other 
MPS cases suggested that the mutation would be in one of the several genes involved in GAGs metabolism17. An 
independent search across candidate genes of enzymes known to regulate the metabolism of GAGs was able to 
identify the single mutation that overlapped with the list of variants found to be homozygous in this case. The 
mutation is a frame-shift insertion introducing a premature stop in the IDUA gene (c.19_20insCGGCCCCC). 
The mutation is very likely to be detrimental to the gene's function because it produces a truncated protein. 
The new protein is not only shorter (108 instead of 655 amino acids) but also completely out of frame with no 
significant overlap with the wild type protein. The mutated product lacks the glycosidase hydrolase domain, 
the key domain of the protein47,48. In addition, expression levels were undetectable in the spleen consistent with 
nonsense-mediated decay49.
The second case of MPS I was in a dilute Boston Terrier with a similar clinical presentation and was also 
homozygous for the same IDUA mutation. This mutation was not found in 150 Boston Terrier samples in either 
the heterozygous or homozygous state indicating that its allele frequency is not very high in the general popu-
lation of the breed. The two cases shared distinctive coat colors that are not due to their MPS disease. The AKC 
breed standard for the Boston Terrier disqualifies these coat colors. These two puppies both came from the south-
eastern United States and were purchased from breeders specializing in the disqualifying coat colors. The coat 
colors are recessive so in order to produce many puppies with these coat colors recent inbreeding likely occurred. 
While the allele frequency is low in the general population of Boston Terriers it is likely higher within the off color 
dogs.
IDUA enzyme deficiency is the known cause of MPS type I in humans1, mice50, cats51, and Plott Hound dogs30. 
Previous unpublished reports have added Boston Terriers to this growing list, however the causative variants were 
never identified in this breed16. Repeated reporting of MPS I in Boston Terriers suggests that this mutation could 
be in the breed, however the coat colors of the affected dogs were not reported. Thus, it is unknown whether this 
mutation exists in coat colors recognized by AKC. It is also possible that the breed has more than one mutation 
causing MPS. The insertion mutation is novel compared to the one established in Plott Hounds and explained by 
SNP mutation in the donor splice site52,53.
This study identified the causative mutation of a spontaneous canine model for human MPS I in the Boston 
Terriers. The identification of the causative variant will enable easier diagnosis of similar cases in the future and 
selective breeding to avoid the spread of this disease in the breed. Application of WGS to identify the causative 
mutation of MPS in Boston Terriers not only enriches our knowledge about the molecular mechanisms of this 
debilitating diseases but also augments recent studies to prove the efficiency of this technique in canine rare dis-
ease gene discovery45,46.
Methods
ethics statement. The dogs are privately owned and informed consent was obtained from the dog owners 
for the participation of the dogs in the study. The study was approved by the UC Davis IACUC (Protocols # 18561 
and 21084). Principal Investigator: Danika L. Bannasch. Institution: University of California, Davis. Active pro-
tocols are reviewed annually. This institution is accredited by the Association for Assessment and Accreditation 
of Laboratory Animal Care, International (AAALAC). This institution has an Animal Welfare Assurance on file 
with the Office of Laboratory Animal Welfare (OLAW). The Assurance Number is A3433-01. The IACUC is con-
stituted in accordance with U.S. Public Health Service (PHS) Animal Welfare Policy and includes a member of 
the public and a non-scientist. The study was performed in accordance with relevant guidelines and regulations.
ophthalmic examination. An ophthalmic examination was performed using slit lamp biomicroscopy 
(SL-17 Slit-Lamp, Kowa Optimed, Inc., Torrance, CA, USA) and binocular indirect ophthalmoscopy (Vantage 
Plus Wireless, Keeler Instruments Inc., Broomall, PA, USA) using a 2.2 panretinal indirect lens (Volk Optical, 
Inc., Mentor, OH, USA). Tear production was evaluated with the Schirmer tear test (Merck Animal Health, 
Millsboro, DE) while intraocular pressure was assessed with rebound Tonometry (TonoVet; Icare Finland Oy, 
Espoo, Finland).
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Radiological assessment. X-ray studies were done using Summit Industries Model L177-01 (Summit 
Industries, 2901 W Lawrence Ave, Chicago, IL. 60625). Magnetic resonance imaging was done using 1.5-T scan-
ner (General Electric Signa LX, Milwaukee, WI).
Histopathological analysis. As described previously54, tissue sections were processed and embedded for 
routine paraffin sectioning. Tissue sections were cut at 4uM thickness on a rotary microtome (Leica), and stained 
for routine hematoxylin and eosin (H&E) using an autostainer (Dako). Serial, unstained sections were subse-
quently cut and stained with periodic acid-Schiff (PAS) or alcian blue methods. All slides were visualized with 
a clinical microscope (Olympus Bx-43) and representative images were obtained on an Olympus DP-72 camera 
using CellSens Entry acquisition software version 1.18, build16686 (Olympus)55.
Urine GAGs analysis. For the first dog, urine spot test for MPS was performed by the University of 
Pennsylvania, School of Veterinary Medicine, PennGen testing laboratory and was reported as positive for MPS. 
For the second dog, urine GAGs were analyzed at the Stanford Clinical Biochemical Genetics Laboratory by 
quantitative assay (dimethylmethylene blue binding) and thin-layer chromatography.
Whole genome sequencing. Frozen tissue was processed to extract 2 µg of high-quality input gDNA 
(Gentra Puregene DNA purification extraction kit, Qiagen, Valencia, CA). Qubit (Thermo Fisher Scientific 
Inc) was used for accurate DNA quantification using a fluorometric-based approach. DNA shearing was done 
using Covaris E220 sonicator followed by selection of 400 bp insert size fragments. PCR-free library prep kit was 
used to avoid PCR induced bias. Sequencing was performed in one lane on the Illumina HiSeq4000 platform in 
UC-Davis sequencing facility for 150 cycles in paired end mode.
Bioinformatics analysis. A pipeline was implemented to identify the putatively deleterious protein coding 
variants. The process started by pre-processing of sequencing reads to remove sequencing adaptors and low qual-
ity sequences using Trimmomatic software package (V 0.36) “command line options: ILLUMINACLIP:$TRIM/
adapters/TruSeq3-PE.fa:2:30:10:1 SLIDINGWINDOW:4:2 MINLEN:20”56. Orphan reads were excluded and 
only long enough paired-end reads (>20 bp) were kept. High quality reads were aligned to the UCSC dog ref-
erence genome using the BWA-MEM algorithm of BWA software package (v0.7.7) “command line options: -t 
8 –M”57. BAM files were generated and sorted using SAMTools (v1.3.1)58 and indexed using Picard software 
(release 1.113)59. Following their best practice recommendations, GATK software package allowed additional step 
of base quality recalibration to adjust for possible systematic technical errors of sequencing quality scoring60. Base 
quality recalibration was done using a list of 11,034,217 known SNPs and 4,947,081 known INDELS generated by 
aggressive quality filtration of the 100 dog database of variants using the VariantFiltration tool of GATK to mark 
untrusted variants60 and the view tool of bcftools(v1.2) to exclude them out. Variant calling was done using GATK 
HaplotypeCaller (v3.5)60. Functional effects of variants were annotated using Variant Effect Predictor (VEP v85) 
made by Ensembl61. NCBI annotation was used for detection of genome errors. NCBI gene models are primarily 
based on RefSeq transcripts and thus overcome genome assembly errors. The NCBI sequences that do not match 
the reference assembly are annotated for possible assembly errors62. Phasing analysis of the deleterious heterozy-
gous mutation was done using whatshap 0.1863.
Sanger sequencing. PCR primers were designed to amplify the candidate variant in the IDUA gene (for-
ward primer: GGAGCCCTCACCAGAAGC, and reverse primer AGACCACCCCTCCACAAAAG). The reac-
tion included 14.24 μl water, 5 μl 5x KAPA LongRange Buffer, 1.5 μl MgCl2 (25 mM), 0.5 μl dNTP (10 mM), 0.63 μl 
of each forwa rd and reverse primers (20 μM), 0.25 μl of KAPA LongRange HotStart DNA  Polymerase (2.5U/
µL) (Kapa Biosystems, Wilmington, MA, USA), 1.25 μl dimethyl sulfoxide (5%), and 1 μl of template genomic 
DNA. The reaction mixtures were subjected to a thermal cycling program of 95 °C for 5 min, followed by 35 cycles 
of 95 °C for 30 sec, 58 °C for 30 sec, and 72 °C for 1 min and final elongation stage of 72 °C for 1 min. The PCR 
products were purified using ExoSap (Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to manu-
facturer's instructions and sequenced using the Sanger sequencing. Products were aligned to the UCSC genome 
browser (genome.ucsc.edu/).
Semi-quantitative RT-PCR. RNA was extracted from the patient's spleen sample and a matching sample 
from another unaffected Boston Terrier’using RNeasy Plus Tissue Mini Kit (Qiagen, Valencia, CA, USA). cDNA 
was prepared using QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA, USA). The RT PCR reaction 
was performed using IDUA primers designed on Primer3 while RPS5 primers were designed as recommended by 
Brinkhof et al. (Table 1)64,65. Each reaction included 14.3 μl water, 2 μl 5x Buffer with MgCl2, 1 μl dNTP (20 mM), 
0.8 μl of each forward and reverse primers (20 μM), 0.1 μl of HotStarTaq. DNA Polymerase (Qiagen, Valenica, 
CA, USA), and 1 μl of cDNA made from1000 ng of RNA. Amplified products were visualized on a 2% agarose gel
Data availability
Whole-genome sequencing files reported in this paper can be found in the NCBI Sequence Read Archive (SRA 
Bioproject no. PRJNA575092).
Forward Primer (5’→3’) Reverse Primer (5’→3’)
IDUA AGCTCAACCTGGCCTATGTG TCAGAGCAGGCGTCGTAGTA
RPS5 TCACTGGTGAGAACCCCCT CCTGATTCACACGGCGTAG
Table 1. Primers used for semi-qPCR.
8Scientific RepoRtS |         (2020) 10:6558  | https://doi.org/10.1038/s41598-020-63451-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
Received: 1 October 2019; Accepted: 6 March 2020;
Published: xx xx xxxx
References
 1. Neufeld, E. F. & Muenzer, J. In The Metabolic & Molecular Bases of Inherited Disease. 8th Edition. Vol. 3 (eds. C. R. Scriver et al.) Ch. 
136, 3421–3452 (McGraw-Hill Professional, 2001).
 2. Coutinho, M. F., Lacerda, L. & Alves, S. Glycosaminoglycan storage disorders: a review. Biochem. Res. Int. 2012, 471325, https://doi.
org/10.1155/2012/471325 (2012).
 3. Wolf, D. A. et al. Gene therapy for neurologic manifestations of mucopolysaccharidoses. Expert. Opin. Drug. Deliv. 12, 283–296, 
https://doi.org/10.1517/17425247.2015.966682 (2015).
 4. Bigger, B. W., Begley, D. J., Virgintino, D. & Pshezhetsky, A. V. Anatomical changes and pathophysiology of the brain in 
mucopolysaccharidosis disorders. Mol. Genet. Metab. https://doi.org/10.1016/j.ymgme.2018.08.003 (2018).
 5. Morishita, K. & Petty, R. E. Musculoskeletal manifestations of mucopolysaccharidoses. Rheumatology 50(Suppl 5), v19–25, https://
doi.org/10.1093/rheumatology/ker397 (2011).
 6. Braunlin, E. A. et al. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J. Inherit. 
Metab. Dis. 34, 1183–1197, https://doi.org/10.1007/s10545-011-9359-8 (2011).
 7. Ashworth, J. L., Biswas, S., Wraith, E. & Lloyd, I. C. The ocular features of the mucopolysaccharidoses. Eye 20, 553–563, https://doi.
org/10.1038/sj.eye.6701921 (2006).
 8. Summers, C. G. & Ashworth, J. L. Ocular manifestations as key features for diagnosing mucopolysaccharidoses. Rheumatology 
50(Suppl 5), v34–40, https://doi.org/10.1093/rheumatology/ker392 (2011).
 9. Muenzer, J. Overview of the mucopolysaccharidoses. Rheumatology 50(Suppl 5), v4–12, https://doi.org/10.1093/rheumatology/
ker394 (2011).
 10. Constantopoulos, G., Dekabian, A. S. & Scheie, H. G. Heterogeneity of disorders in patients with corneal clouding, normal intellect, 
and mucopolysaccharidosis. Am. J. Ophthalmol. 72, 1106–1117 (1971).
 11. van de Kamp, J. J., Niermeijer, M. F., von Figura, K. & Giesberts, M. A. Genetic heterogeneity and clinical variability in the Sanfilippo 
syndrome (types A, B, and C). Clin. Genet. 20, 152–160 (1981).
 12. Beck, M., Glossl, J., Grubisic, A. & Spranger, J. Heterogeneity of Morquio disease. Clin. Genet. 29, 325–331 (1986).
 13. Ashworth, J. L., Biswas, S., Wraith, E. & Lloyd, I. C. Mucopolysaccharidoses and the eye. Surv. Ophthalmol. 51, 1–17, https://doi.
org/10.1016/j.survophthal.2005.11.007 (2006).
 14. Pollard, L. M., Jones, J. R. & Wood, T. C. Molecular characterization of 355 mucopolysaccharidosis patients reveals 104 novel 
mutations. J. Inherit. Metab. Dis. 36, 179–187, https://doi.org/10.1007/s10545-012-9533-7 (2013).
 15. Kadali, S., Naushad, S. M., Radha Rama Devi, A. & Bodiga, V. L. Biochemical, machine learning and molecular approaches for the 
differential diagnosis of Mucopolysaccharidoses. Mol. Cell Biochem. 458, 27–37, https://doi.org/10.1007/s11010-019-03527-6 
(2019).
 16. Haskins, M. E., Giger, U. & Patterson, D. F. In Fabry Disease: Perspectives from 5 Years of FOS (eds A. Mehta, M. Beck, & G. Sunder-
Plassmann) (2006).
 17. Haskins, M. E. Animal models for mucopolysaccharidosis disorders and their clinical relevance. Acta Paediatr. 96, 56–62, https://
doi.org/10.1111/j.1651-2227.2007.00211.x (2007).
 18. Kol, A. et al. Companion animals: Translational scientist's new best friends. Sci. Transl. Med. 7, 308ps321, https://doi.org/10.1126/
scitranslmed.aaa9116 (2015).
 19. Gurda, B. L., Bradbury, A. M. & Vite, C. H. Canine and Feline Models of Human Genetic Diseases and Their Contributions to 
Advancing Clinical Therapies. Yale J. Biol. Med. 90, 417–431 (2017).
 20. Shull, R. M. & Walker, M. A. Radiographic findings in a canine model of mucopolysaccharidosis I. Changes associated with bone 
marrow transplantation. Invest. Radiol. 23, 124–130 (1988).
 21. Walkley, S. U. et al. Abnormal neuronal metabolism and storage in mucopolysaccharidosis type VI (Maroteaux-Lamy) disease. 
Neuropathol. Appl. Neurobiol. 31, 536–544, https://doi.org/10.1111/j.1365-2990.2005.00675.x (2005).
 22. Spellacy, E., Shull, R. M., Constantopoulos, G. & Neufeld, E. F. A canine model of human alpha-L-iduronidase deficiency. Proc. Natl 
Acad. Sci. USA 80, 6091–6095, https://doi.org/10.1073/pnas.80.19.6091 (1983).
 23. Aronovich, E. L. et al. Canine heparan sulfate sulfamidase and the molecular pathology underlying Sanfilippo syndrome type A in 
Dachshunds. Genomics 68, 80–84, https://doi.org/10.1006/geno.2000.6275 (2000).
 24. Yogalingam, G., Pollard, T., Gliddon, B., Jolly, R. D. & Hopwood, J. J. Identification of a mutation causing mucopolysaccharidosis 
type IIIA in New Zealand Huntaway dogs. Genomics 79, 150–153, https://doi.org/10.1006/geno.2002.6699 (2002).
 25. Berman, L. F. P. et al. In Proceedings of the 2nd International Conference: Advances in Canine and Feline Genomics.
 26. Jolly, R. D. et al. Mucopolysaccharidosis type VI in a Miniature Poodle-type dog caused by a deletion in the arylsulphatase B gene. 
N. Z. Vet. J. 60, 183–188, https://doi.org/10.1080/00480169.2011.642791 (2012).
 27. Ray, J. et al. Cloning of the canine beta-glucuronidase cDNA, mutation identification in canine MPS VII, and retroviral vector-
mediated correction of MPS VII cells. Genomics 48, 248–253, https://doi.org/10.1006/geno.1997.5189 (1998).
 28. Silverstein Dombrowski, D. C. et al. Mucopolysaccharidosis type VII in a German Shepherd Dog. J. Am. Vet. Med. Assoc. 
224(553–557), 532–553 (2004).
 29. Hytonen, M. K. et al. A novel GUSB mutation in Brazilian terriers with severe skeletal abnormalities defines the disease as 
mucopolysaccharidosis VII. PLoS one 7, e40281, https://doi.org/10.1371/journal.pone.0040281 (2012).
 30. Shull, R. M. et al. Canine alpha-L-iduronidase deficiency. A model of mucopolysaccharidosis I. Am. J. Pathol. 109, 244–248 (1982).
 31. Shull, R. M. et al. Morphologic and biochemical studies of canine mucopolysaccharidosis I. Am. J. Pathol. 114, 487–495 (1984).
 32. Hoeppner, M. P. et al. An improved canine genome and a comprehensive catalogue of coding genes and non-coding transcripts. 
PLoS one 9, e91172, https://doi.org/10.1371/journal.pone.0091172 (2014).
 33. Lucot, K. L. et al. A Missense Mutation in the Vacuolar Protein Sorting 11 (VPS11) Gene Is Associated with Neuroaxonal Dystrophy 
in Rottweiler Dogs. G3 8, 2773–2780, https://doi.org/10.1534/g3.118.200376 (2018).
 34. Brown, E. A. et al. FGF4 retrogene on CFA12 is responsible for chondrodystrophy and intervertebral disc disease in dogs. Proc. Natl 
Acad. Sci. USA 114, 11476–11481, https://doi.org/10.1073/pnas.1709082114 (2017).
 35. Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. J. Mol. Biol. 215, 403–410, https://
doi.org/10.1016/S0022-2836(05)80360-2 (1990).
 36. Zerbino, D. R. et al. Ensembl 2018. Nucleic Acids Res, https://doi.org/10.1093/nar/gkx1098 (2017).
 37. Sanger, F., Nicklen, S. & Coulson, A. R. DNA sequencing with chain-terminating inhibitors. Proc. Natl Acad. Sci. USA 74, 5463–5467 
(1977).
 38. Pulst, S. M. Genetic linkage analysis. Arch. Neurol. 56, 667–672 (1999).
 39. Hong, E. P. & Park, J. W. Sample size and statistical power calculation in genetic association studies. Genomics Inf. 10, 117–122, 
https://doi.org/10.5808/GI.2012.10.2.117 (2012).
 40. Daiger, S. P. et al. Targeted high-throughput DNA sequencing for gene discovery in retinitis pigmentosa. Adv. Exp. Med. Biol. 664, 
325–331, https://doi.org/10.1007/978-1-4419-1399-9_37 (2010).
9Scientific RepoRtS |         (2020) 10:6558  | https://doi.org/10.1038/s41598-020-63451-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
 41. Lin, X. et al. Applications of targeted gene capture and next-generation sequencing technologies in studies of human deafness and 
other genetic disabilities. Hear. Res. 288, 67–76, https://doi.org/10.1016/j.heares.2012.01.004 (2012).
 42. Mamanova, L. et al. Target-enrichment strategies for next-generation sequencing. Nat. Methods 7, 111–118, https://doi.org/10.1038/
nmeth.1419 (2010).
 43. Broeckx, B. J. et al. Improved canine exome designs, featuring ncRNAs and increased coverage of protein coding genes. Sci. Rep. 5, 
12810, https://doi.org/10.1038/srep12810 (2015).
 44. Belkadi, A. et al. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants. Proc. 
Natl Acad. Sci. USA 112, 5473–5478, https://doi.org/10.1073/pnas.1418631112 (2015).
 45. Sayyab, S. et al. Whole-Genome Sequencing of a Canine Family Trio Reveals a FAM83G Variant Associated with Hereditary 
Footpad Hyperkeratosis. G3 6, 521–527, https://doi.org/10.1534/g3.115.025643 (2016).
 46. Caduff, M., Bauer, A., Jagannathan, V. & Leeb, T. A single base deletion in the SLC45A2 gene in a Bullmastiff with oculocutaneous 
albinism. Anim. Genet. 48, 619–621, https://doi.org/10.1111/age.12582 (2017).
 47. Henrissat, B. & Bairoch, A. New families in the classification of glycosyl hydrolases based on amino acid sequence similarities. 
Biochem. J. 293(Pt 3), 781–788 (1993).
 48. Davies, G. & Henrissat, B. Structures and mechanisms of glycosyl hydrolases. Structure 3, 853–859, https://doi.org/10.1016/S0969-
2126(01)00220-9 (1995).
 49. Baker, K. E. & Parker, R. Nonsense-mediated mRNA decay: terminating erroneous gene expression. Curr. Opin. Cell Biol. 16, 
293–299, https://doi.org/10.1016/j.ceb.2004.03.003 (2004).
 50. Clarke, L. A. et al. Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene. Hum. Mol. 
Genet. 6, 503–511 (1997).
 51. Haskins, M. E., Jezyk, P. F., Desnick, R. J., McDonough, S. K. & Patterson, D. F. Alpha-L-iduronidase deficiency in a cat: a model of 
mucopolysaccharidosis I. Pediatr. Res. 13, 1294–1297 (1979).
 52. Stoltzfus, L. J. et al. Cloning and characterization of cDNA encoding canine alpha-L-iduronidase. mRNA deficiency in 
mucopolysaccharidosis I dog. J. Biol. Chem. 267, 6570–6575 (1992).
 53. Menon, K. P., Tieu, P. T. & Neufeld, E. F. Architecture of the canine IDUA gene and mutation underlying canine 
mucopolysaccharidosis I. Genomics 14, 763–768 (1992).
 54. Arami, H. et al. Nanomedicine for Spontaneous Brain Tumors: A Companion Clinical Trial. ACS Nano 13, 2858–2869, https://doi.
org/10.1021/acsnano.8b04406 (2019).
 55. Olympus. CellSens acquisition software, https://www.olympus-lifescience.com/en/software/cellsens/.
 56. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120, 
https://doi.org/10.1093/bioinformatics/btu170 (2014).
 57. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760, https://
doi.org/10.1093/bioinformatics/btp324 (2009).
 58. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079, https://doi.org/10.1093/
bioinformatics/btp352 (2009).
 59. Picard Tools, http://broadinstitute.github.io/picard.
 60. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. 
Genome Res. 20, 1297–1303, https://doi.org/10.1101/gr.107524.110 (2010).
 61. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122, https://doi.org/10.1186/s13059-016-0974-4 (2016).
 62. NCBI. The NCBI Eukaryotic Genome Annotation Pipeline, https://www.ncbi.nlm.nih.gov/genome/annotation_euk/process/ (2016).
 63. Martin, M. et al. WhatsHap: fast and accurate read-based phasing. bioRxiv, https://doi.org/10.1101/085050 (2016).
 64. Rozen, S. & Skaletsky, H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol. 132, 365–386 
(2000).
 65. Brinkhof, B., Spee, B., Rothuizen, J. & Penning, L. C. Development and evaluation of canine reference genes for accurate 
quantification of gene expression. Anal. Biochem. 356, 36–43, https://doi.org/10.1016/j.ab.2006.06.001 (2006).
Acknowledgements
This work was funded by Center for Companion Animal Health (CCAH) at UC Davis allocation # 2016-17-
F, Maxine Adler Endowed Chair Funds, and Gordon and Betty Moore Foundation's Data-Driven Discovery 
Initiative through Grant GBMF455 to CTB.
Author contributions
T.A.M. study design, bioinformatic analysis and the structuring and writing of the manuscript. K.D.W. 
pathological analysis. K.L.V., D.M.A. and M.F.K. clinical analysis and follow-up. S.M.T., L.S. and B.A.M. 
ophthalmological analysis. H.A.S. contributed to data analysis. T.M.C. contributed to laboratory assessment. 
M.A. molecular analysis. C.T.B. supervised the bioinformatic analysis. D.L.B. supervised the study design and the 
molecular analysis, co-ordination of the project, and critical review of the manuscript. All authors contributed 
and reviewed the manuscript.
competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-63451-4.
Correspondence and requests for materials should be addressed to T.A.M. or D.L.B.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
1 0Scientific RepoRtS |         (2020) 10:6558  | https://doi.org/10.1038/s41598-020-63451-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2020
